REDWOOD CITY, CA--(Marketwired - December 16, 2013) - Versartis, Inc. today announced the expansion of its management team with the appointment of Joshua T. Brumm as its first Chief Financial Officer. Mr. Brumm will report to Chief Executive Officer Jeffrey L. Cleland, PhD, and will lead the company's financial operations including responsibility for investor relations.
"Josh has a strong track record of building successful companies and building great finance teams," commented Dr. Cleland. "His knowledge and experience in corporate finance, investment banking and commercialization will be invaluable to our management team as we continue to advance Versartis towards a commercial business and further prepare for Phase 3 clinical trials for VRS-317, our long-acting treatment for growth hormone deficiency," Dr. Cleland continued. "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."
Mr. Brumm was most recently Executive Vice President of Finance at Pharmacyclics Inc. (NASDAQ: PCYC), where he was the Principal Financial Officer and Principal Accounting Officer with responsibilities for Corporate Finance, IT, Facilities and Procurement. Previously, as Chief Financial Officer and Senior Vice President for ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), he led the company's 2011 initial public offering and also served in senior leadership roles in International Sales, Corporate Development and Investor Relations. Prior to joining ZELTIQ, Mr. Brumm served as Director of Finance at Proteolix, Inc., a private biotechnology company acquired by Onyx Pharmaceuticals. Earlier in his career, Mr. Brumm held the positions of Investment Banking Associate as a member of the West Coast Healthcare Team at Citigroup Global Markets, Inc. and as an Investment Banking Analyst for the West Coast Healthcare Team at Morgan Stanley. Mr. Brumm holds a BA in Business Administration from the University of Notre Dame.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel long-acting form of human growth hormone, for the treatment of growth hormone deficiency. The company is currently conducting a Phase 2 clinical trial of VRS-317 in children with growth hormone deficiency. Further information on Versartis can be found at www.versartis.com.